SKVI 最新10-Q变化
将 SKVI 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-05-13 与上一份 10-Q · 2025-11-13
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +14 | −8 | ~24 | 44 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~4 | 1 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-05-13
On January 27, 2026 Quoin Pharmaceuticals Announced 1. USA - Quoin Pharmaceuticals Announces “FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome”. Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditio…
On March 25, 2026 Quoin Pharmaceuticals Ltd. provided a clinical and regulatory update from its recent constructive Type C meeting with the U.S. Food and Drug Administration (FDA) for its lead product candidate, QRX003, for the treatment of Netherton Syndrome (NS):
§ FDA indicated that a single Phase 3 study may be sufficient to support marketing approval for QRX003 for Netherton Syndrome, which is an alternative to the traditional expectation for two Phase 3 studies in NS patients originally proposed by the Company.
§ FDA expressed openness to an alternative innovative clinical trial design such as a randomized withdrawal or a randomized delayed start for a pivotal Phase 3 study. Such trial design would likely not include a traditional upfront vehicle or placebo control.
§ Based on the feedback from the meeting, Quoin is implementing FDA recommendations consistent with the meeting outcomes, ensuring its readiness to advance toward registrational Phase 3 development. Quoin will submit clinical data from the ongoing Phase 2 and pediatric investigator studies and plans…
相对上期删除的文字 · 来源:10-Q · 2025-11-13
Our revenue, which we combine from product sales, royalties on patent licenses and license fees (product development fees), was $5,000 for the three months ended September 30, 2025 as compared with $5,000 for the same period ended September 30, 2024. Our revenue, which we combine from product sales,…
Operating expenses decreased to $111,057 for the three months ended September 30, 2025, from $129,969 for the same period ended September 30, 2024. Operating expenses decreased to $397,146 for the nine months ended September 30, 2025, from $405,846 for the same period ended September 30, 2024.
We had other expense of $144,188 for the three months ended September 30, 2025, as compared with other expenses of $161,635 for the three months ended September 30, 2024. We had other expense of $423,531 for the nine months ended September 30, 2025, as compared with other expenses of $489,579 for th…
Our other expense for the three and nine months ended September 30, 2025 consisted mainly of interest expense netted against other income related to the sale of polymer. Our other expense for the three and nine months ended September 30, 2024 consisted mainly of interest expense, netted against a ga…
We recorded a net loss of $250,245 for the three months ended September 30, 2025, as compared with a net loss of $286,604 for the three months ended September 30, 2024. We recorded a net loss of $805,677 for the nine months ended September 30, 2025, as compared with a net loss of $880,425 for the ni…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议